요로감염증 시장 예측(-2030년) : 제품 유형, 치료 유형, 검사 유형, 적응증, 유통 채널, 최종 사용자 및 지역별 세계 분석

According to Stratistics MRC, the Global Urinary Tract Infection Market is accounted for $6.60 billion in 2023 and is expected to reach $11.07 billion by 2030 growing at a CAGR of 7.67% during the forecast period. Urinary Tract Infections is a test of urine to detect and manage a wide range of disorders, such as urinary tract infections, kidney disease and diabetes. UTIs, caused primarily by bacteria entering the urethra and multiplying in the urinary tract, are common medical conditions. It serves the healthcare sector by providing diagnostic tools, antibiotics, and therapeutics tailored for UTI management.

According to the American Academy of Family Physicians (AAFP), in March 2020, by Leonardo Ferreira, kidney stones were a common ailment, with an annual incidence of eight instances per 1,000 persons. As per the same source, around 13% of men and 7% of women may develop a kidney stone during their lifetime, and the total incidence of urinary retention in the US is 4.5 to 6.8 per 1,000 men per year.

Market Dynamics:

Driver:

Increasing prevalence of urinary tract infections

The increasing prevalence of urinary tract infections (UTIs), especially in women, the elderly, and people with weakened immune systems, is driving up demand for diagnostic and treatment options. The aging population, increased knowledge of UTIs, and a growing emphasis on early detection and timely treatment are some of the factors driving the UTI market's growth. Furthermore, the need for novel diagnostics, antibiotics, and preventive measures is highlighted by this market driver, which encourages investment and research in the creation of fresh goods and remedies for UTIs.

Restraint:

Rising instances of antibiotic resistance

Effective treatment of urinary tract infections is becoming more difficult due to the emergence of resistant bacterial strains caused by the overuse and misuse of antibiotics. The need for new therapeutic solutions arises from the fact that this resistance limits the effectiveness of current antibiotics and complicates standard treatment regimens. In order to combat antibiotic resistance in UTI management, research and development efforts must be concentrated in order to find new medications and alternative treatment modalities.

Opportunity:

Adoption of novel diagnostic technologies

Point-of-care diagnostics and rapid molecular testing are instances of advanced diagnostic tools that can help identify UTIs more quickly and accurately. This helps to effectively use antibiotics, addressing the growing concern of antibiotic resistance, and improves patient care by enabling timely treatment. Businesses that invest in cutting-edge UTI diagnostic solutions will profit from the growing need for accurate and efficient diagnostic techniques, which will enhance overall healthcare outcomes and lessen the financial burden of UTI treatment.

Threat:

Lack of awareness

UTIs, common bacterial infections affecting the urinary system, often go undetected due to insufficient public knowledge about their causes, symptoms, and preventive measures. This dearth of awareness hampers early diagnosis and timely medical intervention, leading to complications and increased healthcare costs. However, misconceptions and inadequate information about hygiene practices contribute to the prevalence of UTIs. The lack of awareness not only affects individual health outcomes but also burdens healthcare systems.

COVID-19 Impact:

The overwhelming focus on managing and containing the virus has diverted healthcare resources, attention, and funding away from other medical conditions, including UTIs. Lockdowns, restricted healthcare access, and patient concerns about visiting medical facilities have led to delayed diagnoses and treatments, exacerbating the severity of UTIs. Moreover, the increased use of antibiotics to treat COVID-19-related bacterial infections has contributed to antibiotic resistance, potentially limiting the effectiveness of standard UTI treatments. Supply chain disruptions have also affected the availability of UTI medications and diagnostics.

The antibiotics segment is expected to be the largest during the forecast period

The antibiotics segment expected to have largest share over the anticipated period. A wide variety of medications are used to treat bacterial infections of the urinary tract in the Urinary Tract Infection market's antibiotics segment. Beta-lactam antibiotics, like amoxicillin, and fluoroquinolones, like ciprofloxacin, are frequently prescribed antibiotics for urinary tract infections. Additionally, the goals of ongoing research and development are to reduce side effects, minimize resistance, and improve the effectiveness of these antibiotics.

The clinical laboratories segment is expected to have the highest CAGR during the forecast period

Clinical laboratories segment in the urinary tract infection market is expected to have profitable growth. Clinical laboratories are pivotal in the identification and confirmation of UTIs through the analysis of urine samples, which includes assessing bacterial presence and determining antibiotic susceptibility. These laboratories utilize advanced technologies and testing methods to ensure accurate and timely results, facilitating prompt medical intervention. Moreover, the adoption of automation and molecular diagnostic techniques within these laboratories enhances the efficiency and precision of UTI diagnostics.

Region with largest share:

The Asia-Pacific Urinary Tract Infection market is expanding substantially due to the need for diagnostic and treatment solutions is being driven by rising healthcare costs, better healthcare infrastructure, and increased awareness of UTIs. The increased frequency of UTIs is also attributed to a changing lifestyle and an aging population. Additionally, favourable government initiatives and the growth of pharmaceutical and healthcare companies are driving the regional growth.

Region with highest CAGR:

The market for urinary tract infections is expanding substantially in Europe due to a growing geriatric population and rising public awareness. The market is growing due to risk factors like diabetes and urine incontinence are becoming more common, which is also driving growth in Europe. Additionally, government campaigns to raise awareness of urinary health issues and encourage preventative measures have been crucial in driving market growth in the European Union.

Key players in the market:

Some of the key players in Urinary Tract Infection market include Abbott Laboratories , Acon Laboratories, Inc., Allergan Plc, Arkray, Inc., Astrazeneca Plc, Bayer Ag , Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Elektronika Kft., F. Hoffmann-La Roche Ltd, Glaxosmithkline Plc, Johnson & Johnson, Merck & Co. Inc, Mindray Medical International Limited, Novartis Ag, Pfizer Inc, Roche Diagnostics, Sanofi S.A., Siemens Healthcare, Sysmex Corporation and Urit Medical Electronic Group Co., Ltd.

Key Developments:

In December 2023, Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies. The Agreement is based on a basic agreement on business collaboration in the field of immunoassay. Under the terms of the Agreement, Fujirebio and Sysmex will mutually supply a wide range of reagent materials owned by each company, mainly antigens and antibodies, which are the main raw materials of immunoassay reagents.

In December 2023, AstraZeneca Pharma India has entered into a Memorandum of Understanding (MoU) with Roche Diagnostics India to enhance diagnostics for breast cancer patients, particularly focusing on refining HER2 diagnostics with the latest advancements. This strategic alliance aligns with AstraZeneca's commitment to advancing patient-centric healthcare solutions and Roche Diagnostics' dedication to pioneering diagnostic innovation.

Products Covered:

• Azoles and Amphotericin B
• Cephalosporin
• Nitrofurans
• Penicillin and Combinations
• Quinolones
• Other Products

Treatment Types Covered:

• Antibiotics
• Analgesics
• Antispasmodics
• Other Treatment Types

Test Types Covered:

• Microscopic Urinary Tract Infections
• Biochemical Urinary Tract Infections
• Flow Cytometric Urinary Tract Infections
• Other Test Types

Indications Covered:

• Complicated Urinary Tract Infection
• Neurogenic Bladder Infections
• Recurring Complicated Urinary Tract Infection
• Uncomplicated Urinary Tract Infection
• Other Indications

Distribution Channels Covered:

• Drug Stores
• Gynaecology and Urology Clinics
• Retail Pharmacies
• Other Distribution Channels

End Users Covered:

• Hospitals
• Clinical Laboratories
• Home Healthcare
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Urinary Tract Infection Market, By Product

• 5.1 Introduction
• 5.2 Azoles and Amphotericin B
• 5.3 Cephalosporin
• 5.4 Nitrofurans
• 5.5 Penicillin and Combinations
• 5.6 Quinolones
• 5.7 Other Products

6 Global Urinary Tract Infection Market, By Treatment Type

• 6.1 Introduction
• 6.2 Antibiotics
• 6.3 Analgesics
• 6.4 Antispasmodics
• 6.5 Other Treatment Types

7 Global Urinary Tract Infection Market, By Test Type

• 7.1 Introduction
• 7.2 Microscopic Urinary Tract Infections
• 7.3 Biochemical Urinary Tract Infections
• 7.4 Flow Cytometric Urinary Tract Infections
• 7.5 Other Test Types

8 Global Urinary Tract Infection Market, By Indication

• 8.1 Introduction
• 8.2 Complicated Urinary Tract Infection
• 8.3 Neurogenic Bladder Infections
• 8.4 Recurring Complicated Urinary Tract Infection
• 8.5 Uncomplicated Urinary Tract Infection
• 8.6 Other Indications

9 Global Urinary Tract Infection Market, By Distribution Channel

• 9.1 Introduction
• 9.2 Drug Stores
• 9.3 Gynaecology and Urology Clinics
• 9.4 Retail Pharmacies
• 9.5 Other Distribution Channels

10 Global Urinary Tract Infection Market, By End User

• 10.1 Introduction
• 10.2 Hospitals
• 10.3 Clinical Laboratories
• 10.4 Home Healthcare
• 10.5 Other End Users

11 Global Urinary Tract Infection Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Abbott Laboratories
• 13.2 Acon Laboratories, Inc.
• 13.3 Allergan Plc
• 13.4 Arkray, Inc.
• 13.5 Astrazeneca Plc
• 13.6 Bayer Ag
• 13.7 Beckman Coulter, Inc.
• 13.8 Bio-Rad Laboratories, Inc.
• 13.9 Elektronika Kft.
• 13.10 F. Hoffmann-La Roche Ltd
• 13.11 Glaxosmithkline Plc
• 13.12 Johnson & Johnson
• 13.13 Merck & Co. Inc
• 13.14 Mindray Medical International Limited
• 13.15 Novartis Ag
• 13.16 Pfizer Inc
• 13.17 Roche Diagnostics
• 13.18 Sanofi S.A.
• 13.19 Siemens Healthcare
• 13.20 Sysmex Corporation
• 13.21 Urit Medical Electronic Group Co., Ltd.